A Director at Fate Therapeutics (FATE) is Selling Shares


Today, a Director at Fate Therapeutics (FATE), Amir Nashat, sold shares of FATE for $7.13M.

See today’s analyst top recommended stocks >>

Currently, Fate Therapeutics has an average volume of 555.8K.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $17.33, reflecting a 9.1% upside.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts